Profil
Stuart Williams is the founder of Bio-Leonhardt.
He held the title of Vice President-Research & Development at Bio-Leonhardt.
Postes actifs de Stuart Williams
| Sociétés | Poste | Début |
|---|---|---|
Bio-Leonhardt
 Bio-Leonhardt Medical SpecialtiesHealth Technology Bio-Leonhardt is an American company that specializes in bioelectric stimulation sequences to reverse fibrosis and convert scar tissue into new beating heart muscle. The company has patented bioelectric signal sequences for stem cell differentiation and follistatin expression, which are key to managing and recovering from advanced heart failure. The company's platform technology components include a bioelectric stimulator, signals and sequences for precise control of regeneration promoting proteins, and a patented stem cell differentiation into heart muscle signal within myocardial scar tissue. The company also has a patent-pending angiogenic bioelectric signal sequence for mature new blood vessel growth and a real-time inflammation reading and management sequence. The company's products are in early stage development and are not yet proven safe or effective in statistically significant controlled clinical studies. The company was founded by Stuart Williams, and the CEO is Howard J. Leonhardt. | Fondateur | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Bio-Leonhardt
Bio-Leonhardt Medical SpecialtiesHealth Technology Bio-Leonhardt is an American company that specializes in bioelectric stimulation sequences to reverse fibrosis and convert scar tissue into new beating heart muscle. The company has patented bioelectric signal sequences for stem cell differentiation and follistatin expression, which are key to managing and recovering from advanced heart failure. The company's platform technology components include a bioelectric stimulator, signals and sequences for precise control of regeneration promoting proteins, and a patented stem cell differentiation into heart muscle signal within myocardial scar tissue. The company also has a patent-pending angiogenic bioelectric signal sequence for mature new blood vessel growth and a real-time inflammation reading and management sequence. The company's products are in early stage development and are not yet proven safe or effective in statistically significant controlled clinical studies. The company was founded by Stuart Williams, and the CEO is Howard J. Leonhardt. | Health Technology |
